(d) Exhibits

99.1   Press release, dated January 10, 2008, regarding the FDA's acceptance for
       filing of the Company's NDA for BEMA™ Fentanyl.

99.2   Press release, dated January 14, 2008, regarding the Company's expansion of
       its clinical development program for BEMA™ Fentanyl.

This Current Report on Form 8-K and the exhibits hereto may contain, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions and other statements identified by words such as "may", "could", "would", "should", "believes", "expects", "anticipates", "estimates", "intends", "plans" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).